10-Q: Corteva Q3 Sees Sales Surge, Operating EBITDA Rebound

Corteva, Inc. reported a significant improvement in Q3 net loss and strong nine-month net income, driven by volume growth and strategic cost actions, alongside plans for a tax-free spin-off of its Seed and Crop Protection businesses.

Summary

• Net sales for the three months ended September 30, 2025, increased by 13% to $2,618 million, compared to $2,326 million in the same period last year, driven by a 12% volume increase and 2% favorable currency impact.
• Net sales for the nine months ended September 30, 2025, rose 4% to $13,491 million, up from $12,930 million in the prior year, reflecting a 5% volume increase and 1% price increase.
• Operating EBITDA for Q3 2025 significantly improved to $49 million, compared to a loss of $(100) million in Q3 2024, primarily due to Seed and Crop Protection volume growth and favorable Seed product mix.
• Operating EBITDA for the nine months ended September 30, 2025, increased 19.3% to $3,402 million, up from $2,851 million in the prior year, driven by Seed pricing improvements and Crop Protection volume growth.
• Net loss for Q3 2025 was $(318) million, an improvement from a net loss of $(521) million in Q3 2024.
• Net income for the nine months ended September 30, 2025, was $1,654 million, a substantial increase from $958 million in the prior year.
• Diluted earnings per share (EPS) for Q3 2025 improved to $(0.47) from $(0.76) in Q3 2024, and for the nine months, it increased to $2.41 from $1.35.
• The company returned approximately $1.1 billion to shareholders during the nine months ended September 30, 2025, through share repurchases and common stock dividends.
• Corteva announced its intent on October 1, 2025, to separate its Seed and Crop Protection businesses into two standalone, publicly traded companies via a tax-free spin-off.

Sentiment

Score: 7

Explanation: The company demonstrated strong operational improvements with significant growth in sales and Operating EBITDA, and a substantial increase in nine-month net income. Strategic initiatives like the proposed separation and ongoing share repurchases are positive. However, the Q3 net loss, increased debt, and substantial ongoing legal liabilities, particularly related to PFAS, introduce considerable uncertainty and risk, tempering overall sentiment.

Positives

• Net sales for Q3 2025 increased by 13% to $2,618 million, driven by strong volume growth (12%) and favorable currency (2%).
• Net sales for the nine months ended September 30, 2025, grew 4% to $13,491 million, with volume up 5% and price up 1%.
• Operating EBITDA for Q3 2025 showed a significant turnaround, reaching $49 million compared to a $(100) million loss in Q3 2024.
• Operating EBITDA for the nine months ended September 30, 2025, increased 19.3% to $3,402 million, reflecting strong operational performance.
• Net loss for Q3 2025 improved to $(318) million from $(521) million in Q3 2024.
• Net income for the nine months ended September 30, 2025, rose substantially to $1,654 million from $958 million in the prior year.
• Cost of goods sold as a percentage of net sales decreased for both the three-month (63% vs 67%) and nine-month (51% vs 54%) periods, indicating improved efficiency and lower commodity costs.
• Interest expense decreased to $46 million in Q3 2025 from $66 million in Q3 2024, and to $134 million for the nine months from $173 million, due to lower short-term borrowings and interest rates.
• Other income (expense) net significantly improved, moving from a $(107) million expense in Q3 2024 to a $(23) million expense in Q3 2025, and from a $(319) million expense to a $95 million income for the nine months, partly due to insurance proceeds.
• The company increased its common stock dividend by 5.9% to $0.18 per share in July 2025.
• Corteva completed its $2 billion 2022 Share Buyback Plan and authorized a new $3 billion 2024 Share Buyback Plan, demonstrating commitment to shareholder returns.
• EIDP, Inc. remediated a material weakness in internal control over financial reporting related to intercompany cash flow classification as of June 30, 2025.

Negatives

• The company reported a net loss of $(318) million in Q3 2025, despite improvement from the prior year.
• Income (loss) from discontinued operations after income taxes worsened to a $(10) million loss in Q3 2025 from a $(2) million loss in Q3 2024, and to an $(87) million loss for the nine months from a $45 million income.
• Short-term borrowings and finance lease obligations significantly increased to $2,685 million at September 30, 2025, from $750 million at December 31, 2024.
• Total debt increased to $4,373 million at September 30, 2025, from $2,703 million at December 31, 2024.
• Cash and cash equivalents decreased to $2,509 million at September 30, 2025, from $3,106 million at December 31, 2024.
• Competitive pricing dynamics in Latin America led to a 1% decline in overall price for Q3 2025 and a 2% decline in Crop Protection pricing for the nine months.
• Increased R&D expense ($351 million in Q3 2025 vs. $348 million in Q3 2024; $1,061 million for 9M 2025 vs. $1,037 million for 9M 2024) and SG&A expenses ($725 million in Q3 2025 vs. $671 million in Q3 2024; $2,632 million for 9M 2025 vs. $2,461 million for 9M 2024) due to higher compensation and investment.
• Unfavorable currency impacts led by the Brazilian Real and Turkish Lira partially offset sales growth for the nine-month period.

Risks

• Failure to obtain or maintain necessary regulatory approvals for products, potentially due to funding and staff reductions at U.S. government agencies (EPA, USDA, FDA, HHS).
• Failure to successfully develop and commercialize the company's product pipeline.
• Effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products.
• Effect of changes in agricultural and related policies of governments and international organizations.
• Costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements.
• Effect of climate change and unpredictable seasonal and weather factors.
• Failure to comply with competition and antitrust laws, as evidenced by the ongoing FTC investigation and private class action lawsuits.
• Effect of competition in the company's industry, including competitors establishing intermediary platforms for product distribution.
• Risks related to geopolitical and military conflict.
• Effect of volatility in the company's input costs.
• Risks related to the company's global operations, including foreign currency fluctuations and government restrictions (e.g., Argentina).
• Effect of industrial espionage and other disruptions to the company's supply chain, information technology or network systems.
• Risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the Corteva Separation, including significant PFAS liabilities and ongoing lawsuits (e.g., NJ Statewide Settlement, Ohio MDL, Baker Class Action, SC MDL, EPA CERCLA claims).
• Impact of the company's dependence on third parties with respect to certain raw materials or licenses and commercialization.
• Failure of the company's customers to pay their debts, including customer financing programs.
• Failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions.
• Failure to raise capital through the capital markets or short-term borrowings on terms acceptable to the company.
• Increases in pension and other post-employment benefit plan funding obligations.
• Risks related to pandemics or epidemics.
• Capital markets sentiment towards sustainability matters.
• Challenges to the company's intellectual property rights or defense against intellectual property claims asserted by others (e.g., Inari and Bayer disputes).
• Effect of counterfeit products.
• The company's dependence on intellectual property cross-license agreements.
• Risks related to Corteva's Separation from DowDuPont.
• Risks related to the proposed separation of seed and crop protection businesses, including uncertainty of completion, timing, achievement of objectives, diversion of management attention, unexpected costs, potential negative impact on relationships with stakeholders, potential taxability, increased borrowing costs, and reduced diversification of separated companies.

Future Outlook

Corteva intends to separate its Seed and Crop Protection businesses into two standalone, publicly traded companies in a tax-free spin-off for U.S. federal income tax purposes, with the ultimate timing subject to various conditions including regulatory approvals and readiness of each business. The company expects approximately $1 billion in share repurchases for the full year 2025 under its current buyback plans. The Crop Protection Operations Strategy Restructuring Program is expected to be substantially complete by the end of 2026. Legal proceedings, such as the Bayer dispute, have a pause agreement through mid-January 2026 to enable comprehensive resolution, and trials for FTC lawsuit claims are expected to begin in 2027. The court approval hearing for the NJ Statewide Settlement is scheduled for January 2026.

Management Comments

• Management believes its ability to generate cash from operations and access to capital markets and commercial paper markets will be adequate to meet anticipated cash requirements to fund its operations, including seasonal working capital, capital spending, dividend payments, share repurchases, pension obligations and litigation costs, net of recoveries.
• Corteva's strong financial position, liquidity and credit ratings will provide access as needed to capital markets and commercial paper markets to fund seasonal working capital needs.

Industry Context

The agricultural input industry is experiencing dynamic shifts, with Corteva's results reflecting strong demand for new products in Crop Protection and early deliveries in Seed, particularly in Latin America. The company's focus on price for value strategy in Seed, especially in North America and EMEA, indicates a market willing to pay for advanced technology. However, competitive pricing environments, particularly in Latin America for Crop Protection, highlight ongoing market pressures. The industry also faces increasing regulatory scrutiny, as evidenced by the FTC investigation into anticompetitive conduct and the EPA's designation of PFAS as hazardous substances, which will likely increase compliance costs and litigation risks across the sector. Global operations are subject to currency volatility, as seen with the impacts of the Brazilian Real and Turkish Lira, and government restrictions in highly-inflationary economies like Argentina. The proposed separation of Corteva's businesses aligns with a broader trend in some industries to unlock value by creating more focused, agile entities, though it introduces its own set of execution risks.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• **Bayer Dispute (Agrobacterium Cross-License & E3 Soybeans)**: Bayer filed a breach of contract/declaratory judgment lawsuit in Delaware state court against Corteva, alleging patent infringement and entitlement to royalties for E3 soybean sales. Corteva's motion for partial summary judgment was granted, precluding royalty collection after patent expiration. Legal proceedings are paused through mid-January 2026 for comprehensive resolution.
• **Bayer Dispute (AAD-1 Herbicide Resistance Technology)**: Corteva filed a lawsuit against Bayer for alleged infringement of its patented AAD-1 herbicide resistance technology. The Patent Trial and Appeal Board (PTAB) invalidated three patents in December 2024, which Corteva has appealed. The lawsuit is stayed pending the appeal.
• **Bayer Dispute (Roundup Ready Corn 2 Royalties)**: Corteva filed a lawsuit against Bayer in Delaware state court seeking a declaration that Bayer is not entitled to collect patent royalties on the Roundup Ready Corn 2 trait after patent expiration. Bayer's motion for summary judgment was granted, and Corteva's appeal was heard by the Delaware Supreme Court in May 2025, with a decision anticipated in the second half of 2025. This is also part of the August 2025 Pause Agreement.
• **Inari Disputes (Plant Variety Protection & Patent Infringement)**: Corteva filed a lawsuit against Inari Agriculture, Inc. and Inari Agriculture N.V. alleging illegal obtainment and gene editing of seed technologies, and patent infringement. In May 2025, the federal court dismissed Inari's claims of sham litigation, patent misuse, and state-based deceptive trade practices claims. Trial is expected in the second half of 2026.
• **Federal Trade Commission (FTC) Investigation & Lawsuits**: FTC and ten state attorneys general filed a lawsuit against Corteva and another competitor alleging unfair methods of competition, unlawful conditioning of payments, unreasonably restrained trade, and unlawful monopoly. Several private class action lawsuits were centralized. In January 2025, the federal court dismissed federal damages claims and 13 state consumer protection act claims. Trials are expected to begin in 2027.
• **Lorsban Lawsuits (Chlorpyrifos Exposure)**: Asserted claims for personal injury against former Dow Agrosciences LLC, alleging injuries related to chlorpyrifos exposure from Lorsban insecticide. An accrual has been established for the estimated resolution of certain claims.
• **PFAS Liabilities (MOU with Chemours and DuPont)**: Corteva, DuPont, and Chemours agreed to a 50-50 split of certain qualified PFAS expenses up to $4 billion, with Corteva and DuPont's share limited to $2 billion (Corteva's estimated aggregate share is approximately $600 million).
• **Nationwide Water District Settlement (PFAS Drinking Water Claims)**: Finalized in April 2024 for $1.185 billion in aggregate, resolving all drinking water claims related to PFAS for a defined class of U.S. public water systems. Corteva, EIDP, DuPont, and Chemours were settling companies.
• **NJ Statewide Settlement (Legacy Substances & PFAS)**: Agreed on August 3, 2025, with the State of New Jersey to resolve all outstanding claims related to legacy use of various substances, including PFAS, for $875 million in aggregate cash payments over 25 years (NPV ~$500 million). Corteva recorded a $72 million pre-tax loss for its share in Q2 2025. Court approval is scheduled for January 2026.
• **Ohio Natural Resource Damage Claim (PFAS)**: Preliminarily resolved in December 2023 for $110 million, with Corteva's share under the MOU being approximately $16 million.
• **Baker Class Action (New York, PFOA)**: A settlement in principle was reached in June 2025 for $22 million, plus funding $1 million annually to a medical monitoring fund for five years. An accrual for Corteva's share has been established.
• **Aqueous Film-Forming Foams (AFFF) SC MDL**: Approximately 10,100 filed cases against 3M and other defendants, including EIDP and Chemours (some including Corteva and DuPont), alleging personal injury from AFFF use or contamination. Many cases include fraudulent conveyance claims. The first bellwether personal injury trial is expected in 2026.
• **EPA CERCLA Claim (PFAS)**: In November 2024, the EPA asserted CERCLA claims against DuPont, EIDP, and Corteva related to alleged PFAS contamination from six historical and present sites, demanding cleanup and restoration costs. Discussions are ongoing.
• **Nebraska Department of Environment and Energy, AltEn Facility**: Corteva is part of a Facility Response Group participating in a Voluntary Cleanup Program for an ethanol plant. An accrual was established for Corteva's estimated voluntary contribution to remedial action plans.
• **California Department of Toxic Substances Control, Pittsburg Plant**: A state court lawsuit challenges whether the Pittsburg plant's high purity water system required a permit. Discussions are ongoing, and further litigation is stayed.
• **Divested Neoprene Facility, La Place, Louisiana**: EPA and DOJ dismissed an action against Denka and EIDP in March 2025. A private action mirroring government claims was subsequently filed, adding allegations under RCRA and Clean Water Act. DuPont is defending and indemnifying Corteva in this matter.

Related Party Transactions

• EIDP, Inc. and Corteva, Inc., along with certain consolidated subsidiaries, are party to a Master In-House Banking Agreement to manage cash and liquidity needs. Historically, EIDP earned interest on Corteva's borrowings, but beginning in Q4 2024, no interest has been recognized by EIDP, and amounts due from Corteva are classified within EIDP's equity due to a change in repayment intent.
• As of September 30, 2025, EIDP had a due from Parent of $0 million, down from $129 million at December 31, 2024, classified within the equity section of EIDP's Consolidated Balance Sheets.
• EIDP declared dividends to Corteva, Inc. amounting to $732 million for Q3 2025 and $1,620 million for the nine months ended September 30, 2025. Of these, $372 million (Q3) and $1,260 million (9M) were paid during the period and utilized by Corteva to repay amounts due to EIDP.
• EIDP had payables to Corteva, Inc. of $17 million (current) and $145 million (noncurrent) at September 30, 2025, related to Corteva's indemnification liabilities to Dow and DuPont per the Separation Agreements.

Stakeholder Impact

• **Shareholders**: Positive impact from increased common stock dividends (5.9% increase) and ongoing share repurchase programs ($1.1 billion returned in 9M 2025). The proposed separation into two standalone companies aims to unlock shareholder value, but also introduces risks related to execution, costs, and potential impact on stock valuation.
• **Employees**: The Crop Protection Operations Strategy Restructuring Program involves severance and related benefit costs, indicating potential workforce reductions or reallocations. Increased compensation expenses were noted in R&D and SG&A.
• **Customers**: Volume growth in both Seed and Crop Protection segments indicates continued demand for products. Customer financing programs are in place, but there's a risk of customer payment defaults. Competitive pricing, especially in Latin America, could benefit customers.
• **Suppliers**: Obligations for supplier finance programs increased to $160 million at September 30, 2025, from $88 million at December 31, 2024, indicating active use of these programs. Lower commodity costs could impact third-party growers.
• **Creditors**: Total debt increased significantly, particularly short-term borrowings, which could increase financial risk. However, the company maintains access to substantial credit facilities and believes its liquidity is adequate. The May 2025 debt offering was used to refinance maturing notes.
• **Regulatory Authorities**: Ongoing investigations and lawsuits from the FTC, EPA, and various state attorneys general (e.g., New Jersey, Ohio) highlight significant regulatory and legal scrutiny, particularly concerning environmental (PFAS) and antitrust matters. The company's cooperation and settlement agreements aim to resolve these issues.

Next Steps

• Complete the separation of Seed and Crop Protection businesses into two standalone, publicly traded companies, subject to regulatory approvals and other conditions.
• Continue with the Crop Protection Operations Strategy Restructuring Program, expected to be substantially complete by the end of 2026.
• Engage in comprehensive resolution discussions for outstanding disputes and litigation with Bayer through mid-January 2026.
• Proceed with the appeal of the Patent Trial and Appeal Board's decision invalidating three patents related to AAD-1 herbicide resistance technology.
• Prepare for trials related to the FTC lawsuit, expected to begin in 2027.
• Await court approval for the NJ Statewide Settlement, with a hearing scheduled for January 2026.
• Continue to assess the implications of the One Big Beautiful Bill Act (OBBBA) on financial reporting, including the reinstatement of expensing of domestic R&D expenditures.
• Monitor and address EPA CERCLA claims related to alleged PFAS contamination from historical and present sites.
• Continue to make annual installment deposits to the MOU Escrow Account for PFAS liabilities, with 2025 obligations suspended due to the NJ Statewide Settlement.
• Prepare for the trial of the Centre, Alabama water district carpet mill case, expected to be scheduled for January 2026.

Key Dates

Recommendation

Corteva's Q3 and nine-month results demonstrate strong operational momentum, with significant improvements in sales, Operating EBITDA, and net income. The increase in dividends and ongoing share repurchase program are positive signals for shareholders. The proposed separation of Seed and Crop Protection businesses could unlock long-term value by creating more focused entities. However, the company faces substantial and complex legal liabilities, particularly related to PFAS, which have resulted in significant charges and ongoing financial commitments (e.g., NJ Statewide Settlement, MOU with Chemours/DuPont). The increase in total debt, especially short-term borrowings, warrants caution. While operational performance is robust, the inherent uncertainties and potential costs associated with the numerous legal proceedings and the execution risks of a major corporate separation suggest a 'hold' recommendation. Investors should monitor the progress of legal resolutions and the separation process for clearer long-term direction.

Keywords

Corteva, CTVA, SEC Filing, 10-Q, Quarterly Report, Financial Results, Agriculture, Seed, Crop Protection, Operating EBITDA, Net Sales, Earnings Per Share, Share Repurchase, Dividends, Spin-off, Separation, PFAS, Environmental Liabilities, Litigation, Antitrust, Intellectual Property, Restructuring, Debt, Cash Flow, Regulatory Approvals